Compounds > rpr 109881a
Page last updated: 2024-12-11

rpr 109881a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RPR 109881A: a semisynthetic taxoid compound that has a similar mechanism of action to docetaxel [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918259
MeSH IDM0369552

Synonyms (10)

Synonym
tax-109
larotaxel dihydrate
rpr-109881a
rpr 109881a
unii-23k148pyzo
23k148pyzo ,
(1s,2s,4s,7r,8ar,9as,10ar,12as,12br)-1-(benzoyloxy)-4-(((2r,3s)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-2-hydroxy-5,13,13-trimethyl-8-oxo-1,3,4,7,8,9,9a,10,10a,12b-decahydro-2h-2,6-methanocyclodeca[3,4]cyclopropa[4,5]benzo[1,2-b]ox
Q27253757
[(1s,2s,3r,4s,7r,9s,11r,13r,16s)-4,13-diacetyloxy-1-hydroxy-16-[(2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-15,18,18-trimethyl-12-oxo-6-oxapentacyclo[12.3.1.03,11.04,7.09,11]octadec-14-en-2-yl] benzoate;dihydrate
AKOS040747007

Research Excerpts

Overview

RPR 109881A is a new semisynthetic taxoid compound. It has a similar mechanism of action to docetaxel.

ExcerptReferenceRelevance
"RPR 109881A is a new semisynthetic taxoid compound that has a similar mechanism of action to docetaxel. "( Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Fujiwara, K; Hyodo, I; Kashimura, M; Kurata, T; Saeki, T; Shimada, Y; Takashima, S; Tamura, T; Wakasugi, H; Yamamoto, N, 2000)		2
"RPR 109881A was found to be a well-tolerated and promising taxoid agent. "( Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Fujiwara, K; Hyodo, I; Kashimura, M; Kurata, T; Saeki, T; Shimada, Y; Takashima, S; Tamura, T; Wakasugi, H; Yamamoto, N, 2000)		2

Effects

ExcerptReferenceRelevance
"RPR 109881A has a high clearance (mean, 42.6 L/h/m(2)), a large volume of distribution (mean, 952 L/m(2)), and a long terminal half-life (mean, 24 hours)."( Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.
Besenval, M; D'Aloisio, S; Daigneault, L; Eisenhauer, E; Fisher, B; Forand, D; Gelmon, KA; Génier, L; Latreille, J; Lebecq, A; Tolcher, A; Vernillet, L, 2000)		1.29

Pharmacokinetics

RPR 109881A plasma disposition was bi- or triphasic, with a high total plasma clearance, a large volume of distribution, and a long terminal half-life.

ExcerptReferenceRelevance
" The purpose of this phase I study was to characterize the maximum-tolerated dose (MTD), toxicity profile, pharmacokinetic profile, and antitumor effects of this agent."( Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Fujiwara, K; Hyodo, I; Kashimura, M; Kurata, T; Saeki, T; Shimada, Y; Takashima, S; Tamura, T; Wakasugi, H; Yamamoto, N, 2000)		0.56
" Pharmacokinetic evaluation was performed at the first cycle."( Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Fujiwara, K; Hyodo, I; Kashimura, M; Kurata, T; Saeki, T; Shimada, Y; Takashima, S; Tamura, T; Wakasugi, H; Yamamoto, N, 2000)		0.56
" Pharmacokinetic studies indicated that RPR 109881A plasma disposition was bi- or triphasic, with a high total plasma clearance, a large volume of distribution, and a long terminal half-life."( Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Fujiwara, K; Hyodo, I; Kashimura, M; Kurata, T; Saeki, T; Shimada, Y; Takashima, S; Tamura, T; Wakasugi, H; Yamamoto, N, 2000)		0.83

Bioavailability

ExcerptReferenceRelevance
" In addition, the reduced recognition of several compounds by multi-drug-resistance related transport systems has yielded some orally bioavailable compounds with marked in vivo antitumor activity."( Preclinical evaluation of new taxoids.
Bissery, MC, 2001)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.14 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (66.67%)5.53%
Reviews2 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other0 (0.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		7.0153taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		3.110secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
idn 5109
IDN 5109: structure in first source		4.0220
bms184476
[no description available]		3.1110
ConditionIndicatedRelationship StrengthStudiesTrials
Pyrexia
[description not available]		03.4311
Benign Neoplasms
[description not available]		05.4944
Fever
An abnormal elevation of body temperature, usually as a result of a pathologic process.		03.4311
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		05.4944
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		04.7321
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		03.3911
Agranulocytosis
A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).		03.3911
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		03.3911
Experimental Neoplasms
[description not available]		02.9210